1 Extracellular single unit recording techniques were used to compare the eects of (-)-3-amino-1-hydroxypyrrolidin-2-one ((7)-HA-966) and (+)-baclofen on the activity of dopamine-containing neurones in 300 mm slices of rat substantia nigra. Electrophysiological data were compared with the outcome of in vitro binding experiments designed to assess the anity of (7)-HA-966 for g-aminobutyric acid (GABA B ) receptors. 2 Bath application of (7)-HA-966 produced a concentration-dependent inhibition of dopaminergic neuronal ®ring (EC 50 =444.0 mM; 95% con®dence interval: 277.6 mM ± 710.1 mM, n=27) which was fully reversible upon washout from the recording chamber. Although similar eects were observed in response to (+)-baclofen, the direct-acting GABA B receptor agonist proved to be considerably more potent than (7)-HA-966 (EC 50 =0.54 mM; 95% con®dence interval: 0.44 mM ± 0.66 mM, n=29) in vitro. 3 Low concentrations of chloral hydrate (10 mM) were without eect on the basal ®ring rate of nigral dopaminergic neurones but signi®cantly increased the inhibitory eects produced by concomitant application of (7)-HA-966. 4 The inhibitory eects of (7)-HA-966 were completely reversed in the presence of the GABA B receptor antagonists, CGP-35348 (100 mM) and 2-hydroxysaclofen (500 mM). Bath application of CGP-35348 alone increased basal ®ring rate. However, the magnitude of the excitation (9.2+0.3%) was not sucient to account for the ability of the antagonist to reverse fully the inhibitory eects of (7)-HA-966. 5 (7)-HA-966 (0.1 ± 1.0 mM) produced a concentration-dependent displacement of [ 3 H]-GABA from synaptic membranes in the presence of isoguvacine (40 mM). However, the anity of the drug for GABA B binding sites was signi®cantly less than that of GABA (0.0005 potency ratio) and showed no apparent stereoselectivity. 6 These results indicate that while (7)-HA-966 appears to act as a direct GABA B receptor agonist in vitro, its anity for this receptor site is substantially less than that of GABA or baclofen and unlikely to account for the depressant actions of this drug which occur at levels approximately ten fold lower in vivo.
Introduction 3-Amino-1-hydroxypyrrolidin-2-one (HA-966) is representative of an unusual group of centrally-acting muscle relaxant/ antispasmodic drugs which, in addition to sharing a number of behavioural and neurochemical eects, are capable of selectively disrupting the spontaneous electrical activity of mesencephalic dopamine-containing neurones in vivo (Nowycky & Roth, 1977; McMillen et al., 1992) . Used extensively as pharmacological tools in neurochemical studies of dopamine synthesis and release (Roth, 1987) , the mechanisms underlying the unique electrophysiological eects of these compounds have remained elusive. As a chiral molecule, HA-966 exists in enantiomeric forms, each with its own distinct pharmacological pro®le (Singh et al., 1990) . (+)-HA-966 exhibits anxiolytic and neuroprotective ecacy (Vartanian & Taylor, 1991; Dunn et al., 1992; Anthony & Nevins, 1993; Morrow et al., 1993; Goldstein et al., 1994) which has been attributed to its ability to antagonize the glycine allosteric site on the N-methyl-D-aspartate (NMDA) receptor (Henderson et al., 1990; Singh et al., 1990) . (7)-HA-966 has negligible anity for the NMDA receptor complex (Singh et al., 1990) . However, it possesses marked anticonvulsant and sedative eects (Singh et al., 1990; Vartanian & Taylor, 1991) and is considerably more potent in inhibiting the spontaneous activity of mesencephalic dopaminergic neurons in vivo than the (+)enantiomer (Shepard et al., 1995) .
Dierences in potency notwithstanding, the electrophysiological eects of (7) and (+)-HA-966 on substantia nigra (SN) dopamine cells are qualitatively indistinguishable (Shepard et al., 1995) . In addition to inhibiting neuronal ®ring rate, both drugs suppress bursting activity and evoke a pacemaker-like ®ring pattern rarely observed in vivo McMillen et al., 1992) . Previous data indicating that these eects occur independently of an interaction with NMDA receptors (McMillen et al., 1992) have raised the possibility that some of the behavioural eects of (+)-HA-966, particularly those observed in response to high doses of the drug, result from an interaction at the as yet unidenti®ed (7)-HA-966 binding site (Shepard et al., 1995) .
Although the mechanisms underlying the eects of (7)-HA-966 on dopaminergic neurones remains to be established, several lines of evidence point to the possible involvement of gaminobutyric acid (GABA B ) receptors. For example, many of the neurochemical, electrophysiological and behavioural effects of (7)-HA-966 are shared by the putative GABA mi-metic, g-hydroxybutyrate, as well as the prototypical GABA B receptor agonist, baclofen (Waldmeier, 1991; . It has also recently been shown that the inhibitory eects of (+)-and (7)-HA-966 on substantia nigra (SN) dopaminergic neurones in vivo can be reversed by systemic administration of the GABA B antagonist, 3-aminopropane-diethoxymethylphosphonic acid (CGP-35348) (Olpe et al., 1990; Shepard et al., 1995) . Although these ®ndings could be interpreted as suggesting direct involvement of GABAergic mechanisms, preliminary studies have indicated that (7)-HA-966 possesses negligible anity for GABA B binding sites (Waldmeier, 1991) . In an eort to resolve these seemingly paradoxical ®ndings, single unit recording techniques were used to compare the potency of (+)-baclofen and (7)-HA-966 on the activity of nigral dopaminergic neurones in brain slices. The competitive GABA B antagonists CGP-35348 and 2-hydroxysaclofen were also tested for their ability to reverse (7)-HA-966-induced alterations in neuronal activity. Electrophysiological data were compared with the outcome of in vitro binding studies designed to assess the anity of (7)-HA-966 for GABA B receptors. Our results indicate that while (7)-HA-966 appears to act as a direct GABA B agonist in vitro, its potency is substantially less than that of (+)-baclofen and may not fully account for the ability of the drug to suppress dopamine cell ®ring in vivo.
Methods

Single unit recording experiments
Male, Sprague-Dawley rats weighing 100 ± 200 g at the time of experiment were anaesthetized with chloral hydrate (400 mg kg 71 , i.p.) and decapitated. The brain was excised and immersed in an ice-cold saline solution (ACSF) of the following composition (in mM): NaCl 124, KCl 4.0, NaH 2 PO 4 1.25, MgSO 4 1.2, NaHCO 3 26, CaCl 2 2.5, ascorbate 0.15 and glucose 11. A block of tissue containing the SN was prepared over ice and placed on the stage of a manual tissue chopper (Stoelting). Coronal slices (300 mm thickness) were made throughout the anterior-posterior extent of the SN and transferred to a holding dish ®lled with chilled ACSF. Two slices containing the SN (bilateral) were immediately transferred to the stage of an interface perfusion chamber. Tissue was maintained at 34 ± 368C in a humidi®ed oxygen environment and continuously superfused (1.5 ml min 71 ) with oxygenated ACSF equilibrated with 95% O 2 and 5% CO 2 to maintain a pH of 7.35. Slices were maintained in the recording/perfusion chamber for 2 h before the start of the recording studies.
Extracellular single unit activity was recorded from SN neurones by microelectrodes prepared from glass capillary tubing. Electrodes were ®lled with 2 M NaCl and the tips broken back to achieve an in vitro impedance of 2.5 ± 3.5 MO. Electrodes were positioned visually within the pars compacta of the SN by use of a dissecting microscope and micromanipulator equipped with a stepping motor. Electrode potentials were ampli®ed, ®ltered (sampling bandwidth 0.1 ± 4 kHz) and continuously monitored with a digital oscilloscope and audio ampli®er. Pars compacta neurones were identi®ed as dopaminergic on the basis of their unique waveform characteristics and ®ring properties (Grace & Onn, 1989; Yung et al., 1991) . Action potentials from individual dopaminergic neurones were observed and recorded for a minimum of 5 min to establish basal ®ring characteristics. Subsequently, each cell was tested with one or more of the following drugs: (7)-HA-966 (50 mM ± 1 mM), (+)-baclofen (0.25 ± 1.5 mM), chloral hydrate (10 mM), CGP-35348 (100 mM) or 2-hydroxysaclofen (500 mM). Drugs were applied to the perfusion chamber by use of a stopcock assembly that permitted substitution of the normal media with ACSF containing a ®xed concentration of the test compound(s). Drugs were applied to the chamber until a stable response was achieved (see Figure 1 ) and were removed by dilution with control ACSF.
Data acquisition and analysis were conducted by use of an integrated software package for electophysiology (RISI, Symbolic Logic, Dallas, TX). Cumulative rate histograms were compiled in real-time from the output of a window discriminator and displayed with a 10 s bin width. Average ®ring rates were computed from each rate histogram immediately before and during peak drug responses. The data are presented in the text as mean +s.e.mean. Concentrationresponse curves were compiled from groups of cells exposed to a single concentration of (+)-baclofen or (7)-HA-966. Only one cell was tested per slice. Drug-induced alterations in ®ring rate were expressed as a percentage of the pre-drug (control) ®ring rate and plotted as a log function of the concentration administered. EC 50 values, representing the concentration required to inhibit neuronal ®ring by 50%, were computed by use of a four-parameter logistic equation (Inplot, Graphpad Software, San Diego, CA). Omnibus testing of the overall dierences between treatment groups was accomplished by analysis of variance (ANOVA) or in the case of paired comparisons, with a paired t test. Post-hoc comparisons between treatment groups were conducted by the Bonferroni t-test method. Statistical analysis was performed with the SigmaStat (Jandel Scienti®c, San Rafael, CA) and Instat2 (Graphpad Software, San Diego, CA) software packages.
[
H]-GABA B binding
Crude synaptic membranes were prepared from whole brain as previously described (Bowery et al., 1983; Facklam & Bowery, 1993) . Brie¯y, tissue homogenates were prepared in ice-cold 0.32 M sucrose and centrifuged for 10 min at 1,600 g. The P 2 fraction, containing an enriched mixture of synaptic membranes, was collected by centrifugation of the supernatant layer at 31,000 g for 20 min. The resulting pellet was lysed by dispersal in distilled water and recollected by centrifugation at 12,000 g for 20 min. The resulting supernatant together with the upper layer (buy coat) of the pellet were recentrifuged at 48,000 g for 20 min, washed twice in distilled water and stored at 7208C for a minimum of 18 h.
Before use in the binding assay, isolated membrane preparations were subjected to an extensive washing procedure to remove endogenous GABA and other potential contaminants. Frozen membranes were thawed at room temperature and dispersed in ice-cold distilled water. Following centrifugation (13,000 g for 10 min), the pellet was re-washed in distilled water with incubation periods of 15 min between consecutive spins. Subsequently, membranes were suspended in 50 mM Tris-HCl (pH 7.4) containing 2.5 mM CaCl 2 , incubated for 15 min and centrifuged at 13,000 g for 10 min at 48C. Following a ®nal wash in modi®ed Tris buer, membrane pellets were suspended in 100 ml of Tris-HCl and incubated for 10 min at room temperature in the presence of 40 mM isoguvacine HCl, 2.5 mM CaCl 2 , 5 nM [ 3 H]-GABA and either GABA (0.01 ± 0.1 mM) or (7)-HA-966 (0.1 ± 1.0 mM). Non-speci®c binding was evaluated by addition of 100 mM (-)-baclofen. The assay was terminated by centrifugation (7,500 g63 min at 48C) and repeated washing in ice-cold distilled water. Pellets were solubilized overnight in Soluene-350 and transferred to liquid scintillation vials containing 0.4 ml of 0.2 M HCl. Tritium content was determined by liquid scintillation spectrometry. Non-speci®c binding was subtracted from the total amount of radioactivity to yield the amount of speci®c ligand binding. 
Drugs
Results
Stable extracellular recordings were obtained from a total of 76 neurones in the pars compacta of the SN. All cells exhibited electrophysiological characteristics identical to those previously ascribed to neurochemically-identi®ed dopaminergic neurones including: (1) spontaneous, long duration (42 ms), triphasic action potentials; (2) uniform ®ring rates ranging from 2.0 ± 5.1 Hz (mean = 3.3+0.1 Hz) and (3) a pacemaker ®ring pattern (Grace & Onn, 1989; Yung et al., 1991) .
Eects of (7)-HA-966 on dopamine cell activity Bath application of (7)-HA-966 (0.05 ± 1.0 mM) inhibited the ®ring rate of all cells tested (Figure 1) . Although statistically signi®cant (mean dierence=0.16 Hz, paired t=3.14; P=0.035), the magnitude of inhibitory eects produced by the lowest concentration of the drug (50 mM) never exceeded 15% of the control ®ring rate. Higher concentrations produced a proportionately greater inhibition of activity. However, only 2 of 16 cells tested were completely inhibited by the drug. The transient increase in ®ring rate that frequently precedes onset of the inhibitory eects of (7)-HA-966 in vivo Shepard et al., 1995) was never observed in vitro. Although fully reversible upon washout from the chamber, individual cells were slow to respond to bath application of (7)-HA-966. Maximal inhibitory eects of the drug were typically attained after 20 to 30 min of continuous perfusion with comparable intervals required to reverse fully these eects (Figure 1a) . Consequently, concentration-response data were compiled from the peak response of individual neurones tested with a single concentration of (7)-HA-966 and only one cell was tested per slice. Least squares analysis of the data indicated that the concentration of (7)-HA-966 required to inhibit dopamine cell activity by 50% (EC 50 ) averaged 444.0 mM (95% con®dence intervals: 277.6 mM ± 710.1 mM, n=27, Figure 1c ).
Eects of (+)-baclofen on dopamine cell activity
In order to provide a basis for comparison, an additional group of experiments was conducted to assess the sensitivity of nigral dopamine neurones to the inhibitory eects of the prototypical GABA B agonist, (+)-baclofen. As illustrated in Figure 1c , bath application of (+)-baclofen produced a concentration-dependent reduction in ®ring rate (EC 50 =0.54 mM, 95% con®dence intervals: 0.44 mM ± 0.66 mM, n=29). Of nine cells tested with the highest concentration of (+)-baclofen (1.5 mM), seven (78%) were silenced by the drug. The inhibitory eects of (+)-baclofen, like those of (7)-HA-966, were slow to develop, usually requiring more than 20 min to attain a steady-state value. However, the inhibition produced by (+)-baclofen was immediately reversed upon its washout from the chamber (Figure 1b) .
Eects of chloral hydrate on the inhibitory actions of (7)-HA-966
Previous studies have shown that the response of SN dopaminergic neurones to g-hydroxybutyrate is in¯uenced by certain anaesthetics (Diana et al., 1991) . These ®ndings, together with our own results indicating that the inhibitory eects of (7)-HA-966 in vivo are attenuated when ketamine is substituted for chloral hydrate as an anaesthetic (Shepard et al., 1993) , prompted us to examine the eects of the latter compound on the inhibitory eects of (7)-HA-966 in vitro. In these experiments, the average response of ten SN dopamine cells tested with 500 mM (7)-HA-966 was compared to a separate group of cells (n=9) tested with an identical concentration of the drug applied in the presence of 10 mM chloral hydrate. Average basal ®ring rates exhibited by the two treatment groups were not signi®cantly dierent. Bath application of the anaesthetic had no eect on neuronal ®ring rate (Figure 2b ). The magnitude of the inhibition produced by (7)-HA-966 in the presence of chloral hydrate (65% inhibition; Figure 2b ) was only slightly greater than that observed in its absence (48% inhibition; Figure 2a) . However, these differences were marginally signi®cant (2-way repeated measures ANOVA, F 1,17 =4.4, P=0.5).
CGP-35348 and 2-hydroxysaclofen reverse the inhibitory eects of (7)-HA-966
The potential involvement of GABA B receptors in mediating the inhibitory eects of (7) selective antagonists, CGP-35348 (100 mM) and 2-hydroxysaclofen (500 mM). Addition of CGP-35348 (Figure 3a, d ) or 2-hydroxysaclofen (Figure 3b , e) to the bathing solution completely reversed the inhibitory eects of (7)-HA-966 (500 mM). Notably, in contrast to the characteristically slow washout of (7)-HA-966, reversal of the rate-decreasing eects of the drug by both antagonists was complete within ®ve minutes following their introduction into the chamber (Figure  3a-b) . Bath application of CGP-35348 alone increased (9.2+0.3%) the basal ®ring rate of SN dopaminergic neurones (Figure 3c ; mean dierence =70.28 Hz, Paired t=3.67, P=0.04).
Eect of (7) In order to assess directly the anity of (7)-HA-966 for GABA B receptors, the ability of the drug to displace [ 3 H]-GABA from synaptic membranes was determined under conditions in which GABA A receptors were blocked by isoguvacine. As illustrated in Figure 4 , the extent of displacement was concentration-dependent and proportional to the inhibitory eects produced by the drug. However, (7)-HA-966 was signi®cantly less potent than GABA (relative anity =0.0005 GABA) and exhibited no apparent stereoselectivity (data not shown).
Discussion
Previous studies have con®rmed the ability of (7)-HA-966 to modify both the ®ring rate and discharge pattern of nigrostriatal dopamine-containing neurones in the chloral hydrate anaesthetized rat Shepard et al., 1995) . In the present series of experiments, we have extended these ®ndings by demonstrating that the inhibitory eects of Saclofen (500 µM) Figure 3 Eects of CGP-35348 and 2-hydroxysaclofen on the inhibitory actions of (7)-HA-966. (a and b) Rate histograms illustrating the characteristic eects of bath applied (a) CGP-35348 (100 mM) and (b) 2-hydroxysaclofen (500 mM) on the inhibitory response produced by concomitant application of (7)-HA-966 (500 mM). Horizontal bars denote the duration of drug application. (c ± e) The eects of CGP-35348 on dopamine cell activity (c) and the eects of (d) CGP-35348 and (e) 2-hydroxysaclofen on (7)-HA-966-induced inhibition of neuronal activity. Asterisks denote a signi®cant dierence from control values (*P50.05; **P50.01). (n=9) to chloral hydrate (10 mM) in the presence (solid column) and absence (hatched column) of (7)-HA-966 (500 mM). Note that addition of chloral hydrate potentiated the inhibitory eects of (7)-HA-966 (2-way repeated measures ANOVA, F 1,17 =4.4, P=0.05). Asterisks denote a signi®cant dierence from control ®ring rate (Bonferroni t test, P50.001).
the drug persist in nigral brain slices, a preparation presumably devoid of extrinsic aerent input. Although similar in some respects to results obtained in the intact animal, dierences between the pharmacological pro®le of (7)-HA-966 in vitro and in vivo oer insights into the possible mechanisms underlying the electrophysiological eects of the drug. For example, the transient increase in ®ring rate typically preceding onset of the inhibitory actions of (7)-HA-966 in vivo was never observed in vitro. Based on these ®ndings, it seems reasonable to conclude that the excitatory eects of the drug are mediated through one or more aerent pathways which are lost during preparation of the tissue slices. On the other hand, the ability of (7)-HA-966 to inhibit neuronal ®ring rate in vitro would seem to imply that this component of the response is mediated locally ± possibly through a direct interaction with nigral dopaminergic neurones.
In agreement with earlier in vivo studies (Shepard et al., 1995) , high concentrations of (7)-HA-966 (0.5 ± 1 mM) proved capable of completely suppressing neuronal activity in a percentage of cells. Although of similar apparent ecacy, qualitiative dierences appear to exist in the potency of the drug between in vivo and in vitro preparations. Thus, while the average intravenous dose of (7)-HA-966 needed to inhibit dopamine cell activity by 50% in the chloral hydrate anaesthetized rat averaged 5.7 mg kg 71 (Shepard et al., 1995) , relatively high concentrations of the drug (&450 mM) were required to produce similar eects in vitro. Although comparison of EC 50 and ED 50 estimates cannot be made directly, it seems unlikely that a single intravenous dose of less than 50 mmol kg 71 (15 mmol/300 g rat) could result in tissue concentrations approaching 0.5 mM. Further evidence of the attenuated potency of (7)-HA-966 in vitro was obtained from a direct comparison of its eects with those of the prototypical GABA B agonist, (+)-baclofen. Bath application of (+)-baclofen led to a concentration-dependent reduction in dopaminergic neuronal activity. Although qualitatively similar to the eects of (7)-HA-966, (+)-baclofen was over 800 fold more potent in inhibiting dopamine cell ®ring rate in vitro (EC 50 =0.54 mM vs. 444 mM, respectively).
One explanation for the apparent discrepancy in the potency of (7)-HA-966 between in vivo and in vitro preparations concerns the potential in¯uence of chloral hydrate on the responsiveness of nigral dopaminergic neurones to (7)-HA-966. In addition to potentiating the inhibitory eects of a variety of direct-acting dopamine agonists (Kelland et al., 1989; 1990) , recent studies have indicated that chloral hydrate may increase the sensitivitiy of nigral dopaminergic neurones to the rate decreasing eects of g-hydroxybutyrate in vivo (Diana et al., 1991) . Preliminary data have also shown that the inhibitory eects of (7)-HA-966 are attenuated in ketamine-anaesthetized rats (Shepard et al., 1993) . Consistent with these observations, coapplication of a low concentration of chloral hydrate (10 mM) was found to enhance signi®cantly the inhibitory eects of (7)-HA-966 in vitro, although the magnitude of the inhibition produced by (7)-HA-966 in the presence of chloral hydrate was only slightly greater than that observed under control conditions. However, it should be noted that the extent of synergism between these drugs was probably aected by the low concentrations of anaesthetic and a retarded rate of formation of the active metabolites of chloral hydrate (Breimer, 1977) .
Despite the low anity of (7)-HA-966 for GABA B binding sites, the results of the present study indicate that the inhibitory eects of (7)-HA-966 in vitro may derive from a direct interaction with these receptors. Thus, (7)-HA-966 was found to displace the speci®c binding of [ 3 H]-GABA to GA-BA B receptors in a concentration-dependent manner. It is also conceivable that in addition to its weak agonist properties, (7)-HA-966 acts to release endogenous GABA onto GABA B receptors. The comparatively low potency of the drug in inhibiting dopamine cell ®ring (relative potency *0.001(+)-baclofen) was re¯ected by similar dierences between the af®nity of GABA and (7)-HA-966 for the GABA B binding site (relative potency *0.0005 GABA). Although of signi®cantly lower potency than either (+)-baclofen or GABA, the inhibitory eects of (7)-HA-966 were completely reversed by the GABA B antagonists, CGP-35348 (100 mM) and 2-hydroxysaclofen (500 mM). These concentrations are equivalent to or in some cases well below those previously shown to antagonize fully GABA B -mediated postsynaptic potentials or the inhibitory eects of local application of baclofen in brain slices (Olpe et al., 1990; Hausser & Yung, 1994; Benardo, 1995; Guyon & Leresche, 1995; Li & Guyenet, 1995; Morishita & Sastry, 1995) . Notably, reversal of the inhibitory eects of (7)-HA-966 produced by CGP-35348 was frequently accompanied by an overshoot in activity resulting in ®ring rates that were often higher than control values. Modest excitatory effects were also observed in response to CGP-35348 applied in the absence of (7)-HA-966 suggesting that endogenous GABA levels in the brain slice are suciently high to maintain tonic activation of GABA B receptors. Nevertheless, the magnitude of the excitation produced by CGP-35348 (510%), since ®ring rate is a linear function of excitability (Silva & Bunney, 1988; Grace, 1991; Yung et al., 1991) , was not sucient to account for the ability of the drug to reverse the inhibitory eects of (7)-HA-966 completely.
In summary, (7)-HA-966 was found to inhibit the activity of nigral dopaminergic neurones in a concentration-dependent fashion. Although the eects of the drug in vitro could be attributed to its ability to act as a weak GABA B agonist, this mechanism is unlikely to account for the potent inhibitory eects exhibited by low doses of (7)-HA-966 in vivo. Concentration (mM) Figure 4 Inhibition by (7) 
